Nasdaq · CIK 0001628171 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Revolution Medicines, Inc.
RVMD chart by TradingView
PRICE HISTORY
LIVE · NASDAQRVMD chart by TradingView
- REVENUE FY2025 ENDED DEC 2025
- $0.0B
- EBITDA
- $-1.2B
- FREE CASH FLOW
- $-0.9B
- EPS
- $-5.95
- GROSS MARGIN
- —
- ROIC
- —
Q4 FY24ENDED DEC 2024HOVERDRAG ACROSS ANY CHART TO SCRUB ALL 24 · 24 QUARTERS SHOWNVALUATIONGROWTHPROFITABILITY & RETURNSCASH & CAPITALBALANCE SHEET
VALUATION
what you pay for a unit of the business7 CHARTS⤢
P / E RATIO (TTM)
—
⤢
P / SALES (TTM)
—
+20076%50.5x10197.3x
⤢
P / BOOK
3.2x
-30%1.7x4.8x
⤢
EV / EBITDA (TTM)
—
⤢
EV / REVENUE (TTM)
—
⤢
FCF YIELD (TTM)
-7.78%
-3.0pp-13.32%-4.74%
⤢
DIVIDEND YIELD (TTM)
—
GROWTH
is the business getting bigger5 CHARTS⤢
REVENUE
$0.0B
-100%⤢
EBITDA (DERIVED)
$-0.2B
$0.2B⤢
NET INCOME
$-0.2B
$0.2B⤢
EPS (DILUTED)
$-1.17
$0.54⤢
REVENUE GROWTH YOY
-100.00%
-87.7pp-100.00%204.81%
PROFITABILITY & RETURNS
what survives to the bottom, and what it earns on capital4 CHARTS⤢
FCF MARGIN
—
-16462.3pp-16560.65%-98.33%
⤢
RETURN ON CAPITAL
—
⤢
RETURN ON EQUITY (TTM)
-26.49%
-11.7pp-45.00%-14.81%
MARGIN FUNNEL
every line is a share of the same revenue, so they read on one scale — the gaps are what each layer takes out, and net rises above operating when income arrives from outside the businessGROSS MARGIN—
OPERATING MARGIN—
NET MARGIN—
FCF MARGIN—
CASH & CAPITAL
where the money actually goes5 CHARTS⤢
FREE CASH FLOW
$-0.1B
$0.1B⤢
STOCK-BASED COMP
$0.0B
+5468%⤢
CAPITAL EXPENDITURE
$0.0B
+258%⤢
SHARES OUTSTANDING
0.17B
+204%⤢
DIVIDEND / SHARE
—
BALANCE SHEET
how much cushion there is3 CHARTS⤢
CASH & EQUIVALENTS
$0.5B
+765%⤢
TOTAL DEBT
—
⤢
DEBT / EBITDA (TTM)
—
OWNERSHIP
10 LARGEST HOLDERS · WHO OWNS THE FLOATINSTITUTIONS 99.35%INSIDERS 1.88%OTHER / RETAIL 0.00%846 INSTITUTIONAL FILERS
| HOLDER | % HELD | SHARES | VALUE | CHANGE |
|---|---|---|---|---|
| Farallon Capital Management LLC | 6.35% | 13.6M | $2.79B | NEW |
| Blackrock Inc. | 5.23% | 11.2M | $2.30B | +25.6% |
| Janus Henderson Group PLC | 4.56% | 9.8M | $2.00B | -20.6% |
| Baker Bros. Advisors, LP | 4.46% | 9.6M | $1.96B | +1.1% |
| FMR, LLC | 3.95% | 8.5M | $1.74B | -1.4% |
| Vanguard Capital Management LLC | 3.90% | 8.4M | $1.72B | NEW |
| Nextech Invest, Ltd. | 3.55% | 7.6M | $1.56B | +0.0% |
| Vanguard Portfolio Management LLC | 3.50% | 7.5M | $1.54B | NEW |
| Paradigm Biocapital Advisors LP | 3.11% | 6.7M | $1.37B | +0.2% |
| Wellington Management Group, LLP | 2.81% | 6.0M | $1.24B | -13.7% |
AS OF 2026-03-31 · MOST RECENT 13F FILINGS
SOURCE → 10-K · 10-Q · 8-K / GUIDANCE · ALL FILINGS
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.